Allogene's Q1 Earnings In Line With Estimates, Sales Nil [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
In the year-ago period, the company had incurred a loss of 38 cents per share. As ALLO lacks a marketed product in its portfolio, it did not report any sales during the quarter. In the year-ago period, Allogene recorded collaboration revenues worth $0.02 million. Year to date, shares of Allogene have plunged 47% compared with the industry's 6% decline. Image Source: Zacks Investment Research Research & development (R&D) expenses totaled $50.2 million, down 4% from the year-ago quarter's level. General and administrative (G&A) expenses declined 13% year over year to $15.0 million. As of March 31, 2025, Allogene had $335.5 million in cash, cash equivalents and investments compared with $373.1 million as of Dec. 31, 2024. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar) In light of the dynamic macroeconomic environment and the need to preserve capital, Allogene recently implemented strategic cost realignment initiatives aimed at optimizing operations
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCOGlobeNewswire
- Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- Foresight Diagnostics Presents Independent Validation of its CLARITY Minimal Residual Disease (MRD) Assay in Multicenter Study of Frontline DLBCL at the 2025 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-CelGlobeNewswire
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Citigroup Inc. from $8.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
ALLO
Earnings
- 5/13/25 - In-Line
ALLO
Sec Filings
- 6/23/25 - Form 4
- 6/23/25 - Form 4
- 6/23/25 - Form 4
- ALLO's page on the SEC website